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Colorectal cancer is the fourth commonest form of cancer
worldwide with an estimated 678 000 new cases diagnosed in
1985 (Parkin et al., 1993). High incidence rates are found in
Western Europe, North America and Australasia and inter-
mediate rates in Eastern Europe, with the lowest rates found
in sub-Saharan Africa (Boyle et al., 1985). The disease is not
uniformly fatal although there are large differences in sur-
vival according to stage of disease. In advanced colorectal
cancer in which curative resection is possible, 5 year survival
in Dukes' B is 45%, which drops to 30% in Dukes' C
(Morson, 1979). Five year survival in resected Dukes' A is
around 80% and survival following simple resection of an
adenomatous pedunculated polyp containing carcinoma in
situ (or severe dysplasia) or intramucosal carcinoma is
generally close to 100%. It is estimated that there are, how-
ever, still 394 000 deaths annually from colorectal cancer
worldwide (Pisani et al., 1993).
The large difference in survival between early and late
stage disease clearly indicates the advantage in detecting
colorectal cancer at an early stage. The simplest advice is to
ensure that any change in bowel habits or unexpected
presence of blood in the stool should be investigated. Faecal
occult blood testing (FOBT) is aimed at the detection of
early asymptomatic cancer and is based on the assumption
that such cancers will bleed and that small quantities of
blood lost in the stool may be detected chemically or
immunologically. A significant reduction in colorectal cancer
mortality with annual testing using Haemocult has been
reported (Mandel et al., 1993). The cumulative annual mor-
tality rate in the group screened annually was 5.88 per 1000
compared with 8.83 in the control group and 8.33 in the
group screened bienially. The results are of considerable
importance but it is difficult to ignore the observation that
38% of those screened annually and 28% of those screened
biennially underwent at least one colonoscopy during the
study period although it is somewhat reassuring that the
incidence of colorectal cancer was so similar in the three
groups (23, 23 and 26 per 1000 for those screened annually,
those screened biennially and those in the control group
respectively). The authors considered that the likely effect of
colonoscopy, in removing polyps, had not yet affected the
incidence and mortality from colorectal cancer. These
findings are important confirmation that Haemocult screen-
ing may be effective against colorectal cancer and
confirmatory findings from other trials are eagerly awaited.
There are both advantages and disadvantages to FOBT. On
the one hand it is low cost, although the investigation offalse
positives (around 1-3% per test) certainly increases the cost,
and it 'examines' the entire colon and rectum. However,
FOBT is currently characterised by a low sensitivity (with
around 40% of cancers and 80% of adenomas missed by the
test Rozen et al., 1987; Allison et al., 1990) and by detecting
colorectal cancers at stages in the natural history at which
lesions bleed which leads to a short lead-time and the
requirement for frequent testing. Rehydration of the slides
results in increased positivity but also an increased number of
colonoscopies and a decreased specificity of the test. The
costs must be weighed against the benefits before public
health policy on this topic is formulated (Mandel et al.,
1993).
Until a randomised controlled trial is undertaken and
reported, the efficacy of flexible sigmoidoscopy as a screening
test for preventing death from colorectal cancer will remain
unproven. However, there is now a good deal of evidence
supporting infrequent sigmoidoscopy as a potentially effective
screening modality for colorectal cancer. Impressive reduc-
tions in rectal cancer and cancer of the proximal colon have
been reported from demonstration studies: 85% reduction in
21 000 subjects undergoing 'clearing' proctosigmoidoscopy
followed by annual proctosigmoidoscopy with removal of all
lesions detected (Gilbertson and Nelns, 1978); 70% reduc-
tion in risk of colorectal cancer for 10 years following sig-
moidoscopy (Selby et al., 1992); 80% reduction in incidence
following examination mostly performed by flexible sig-
moidoscopy (Newcomb et al., 1992); and an 85% reduction
of rectal cancers achieved by the removal of adenomas
(Atkin et al., 1992). Although the initial examination may be
expensive, there is an advantage that polyps may be removed
at the time of the initial procedure and no follow-up visits
will be required. Use of a 65 cm flexible sigmoidoscope
appears to be the most effective proposition at the present
time since this avoids the more complicated colonoscopy and
yet still covers the region of the large bowel where two-thirds
of cancers arise.
The natural history and the role of several risk factors in
the aetiology of colorectal cancer are becoming more clearly
understood (Fearon and Vogelstein, 1990; Morotomi et al.,
1990) and the genetic events involved in colorectal cancer
susceptibility are being uncovered with increasing frequency
(Bodmer et al., 1987; Hall et al., 1994). The recent rate of
progress in our understanding of the genetics of colorectal
cancer is impressive (Bishop and Thomas, 1990; Bishop and
Hall, 1994). Knowledge oflifestyle risk factors is also becom-
ing clearer. Risk of colorectal cancer appears to be increased
by increasing consumption offat, protein and meat and to be
reduced by increased consumption of fruits and vegetables
(Potter et al., 1993). It has been hypothesised that alterations
to serum triglycerides and/or plasma glucose could be one
possible vehicle for the effects of various aetiological factors
(McKeown-Eyssen, 1994). Thus there are prospects for
primary prevention although it is difficult to know how to
successfully bring about such large-scale alterations to the
diets of large proportions of populations. The large bowel is
not generally considered as a site where the risk of cancer is
liked to cigarette smoling (IARC, 1986) although it has
been recently suggested that it may be an independent risk
factor which may be specifically associated with the early
stages ofcolorectal carcinogenesis (Giovannucci et al., 1994a,
b). However, there is also interesting evidence suggesting that
specific chemopreventive strategies could prove useful in the
prevention of colorectal cancer.
Chemoprevention received a major boost recently with the
demonstration that supplementation of the diet of about
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30 000 Chinese residents of Ling Xian County with vitamin
E. a-carotene and selenium led to a reduction after 5 years of
use of total mortality, total cancer incidence and mortality
and the incidence of cancer of the stomach (Blot et al.. 1993).
Antioxidants have long been leading candidates for chemo-
prevention and the findings regarding the protective effect of
fruits and vegetables in colorectal cancer are consistent with
this possibility. Folate. frcarotene and vitamin E have
received support as being protective in colorectal cancer from
a number of studies as discussed by Ferraroni et al. (1994).
Unusually. there are some data available from randomised
trials on this issue although they are still limited. Although
not statistically significant. there was a reduced number of
cases of colorectal cancer found among Finnish smokers
randomised to cx-tocopherol (68 cases. 8.0 per 10000 per-
son-years) when compared to placebo (81 cases. 9.6 per
10 000) (The Alpha-Tocopherol. Beta-Carotene Cancer Prev-
ention Study Group. 1994): the approximate relative risk
appears to be 0.87. A randomised controlled trial of fr
carotene and vitamins C and E involving 864 patients ran-
domised to one of four treatment arms. who underwent
colonoscopy for polyp identification after 1 year and 4 years.
reported no evidence that either beta-carotene or vitamins C
and E reduced the incidence of adenomas (Greenberg et al..
1994). Although antioxidants are obvious candidates for use
as chemopreventive agents in trials and they may have pro-
tective effects against other cancers and other diseases, poten-
tially including cardiovascular disease (Meydani. 1995). their
potential in colorectal cancer prevention is not proven at the
present time. This is surely an area where more research is
needed to identify effective chemopreventive agents and
where large trials are necessary to prove their effectiveness.
Non-steroidal anti-inflammatory drugs (NSAIDs) have
recently been implicated as potential protective agents against
colorectal cancer and adenomatous polyps. Initial anecdotal
reports noting regression of adenomas in patients with
familial adenomatous polyps have been followed by substan-
tial epidemiological studies. There is a general level of agree-
ment in the finding of a protective effect from such studies.
There are randomised trials of familial adenomatous polyps
demonstrating the regression of adenomas by NSAIDs. For
example. complete regression of rectal polyps was reported in
six of nine patients taking sulindac and partial regression in
three others: in the placebo group, polyps increased in five.
remained unchanged in two and decreased in the remaining
two (Labayle et al.. 1991). In laboratory rodents. piroxicam.
sulindac and aspinrn all have been shown to reduce the
frequency of development of colorectal neoplasia (Skinner et
al.. 1991). The mechanism of any effect remains obscure, as
does the dose required, and it is disappointing that the
randomised intervention trial of low-dose aspirin in United
States physicians was null although this may represent a
situation where the dose given was too low or the period of
use too short to achieve the protective effect (Gann et al..
1993). However, there is a very good case for a controlled
trial of NSAIDs. probably using aspirin, in the prevention of
colorectal cancer (Farmer et al., 1993).
Prospects for prevention of colorectal cancer death are
much brighter than even 10 years ago (Zaridze. 1983). Large
randomi'sed trials of screening with flexible sigmoidoscopy
are very important and there is a strong case for chemo-
prevention trials using aspirin (or another NSAID) and
antioxidants (vitamin E, frcarotene. vitamin C). Successful
outcomes to these trials could see strategies to prevent the
majority of colorectal cancer deaths available to the general
population within a decade. It could also be important to
follow up the consistent observations of protective effects of
hormone replacement therapy in colorectal cancer. where the
risk may be halved in association with six or more years of
use (Calle et al.. 1995).
Coupled with developments in genetics, and even treatment
(Cunningham and Findlay. 1993). colorectal cancer may
emerge as the first major neoplasm which turns out to be
preventable allying successful treatment with successful
prevention strategies using prescription (screening and chemo-
prevention) rather than proscription ('Thou shalt not smoke
or eat a high-fat diet'). A united funding policy and an
internationally co-ordinated research programme would serve
to accelerate this potential.
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